nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—POR—Doxorubicin—liver cancer	0.564	0.712	CbGbCtD
Nilutamide—CYP2C8—Sorafenib—liver cancer	0.0898	0.113	CbGbCtD
Nilutamide—CYP2C19—Sorafenib—liver cancer	0.0753	0.0952	CbGbCtD
Nilutamide—CYP2C9—Sorafenib—liver cancer	0.0626	0.0791	CbGbCtD
Nilutamide—Flutamide—AHR—liver cancer	0.00728	0.681	CrCbGaD
Nilutamide—Interstitial pneumonia—Sorafenib—liver cancer	0.00511	0.0461	CcSEcCtD
Nilutamide—Interstitial lung disease—Sorafenib—liver cancer	0.00349	0.0315	CcSEcCtD
Nilutamide—Flutamide—CYP1A1—liver cancer	0.00226	0.211	CrCbGaD
Nilutamide—Gynaecomastia—Sorafenib—liver cancer	0.00221	0.0199	CcSEcCtD
Nilutamide—Cardiac failure—Sorafenib—liver cancer	0.00184	0.0166	CcSEcCtD
Nilutamide—Dry skin—Sorafenib—liver cancer	0.00164	0.0148	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00162	0.0146	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00158	0.0143	CcSEcCtD
Nilutamide—Erectile dysfunction—Sorafenib—liver cancer	0.00143	0.0129	CcSEcCtD
Nilutamide—Weight decreased—Sorafenib—liver cancer	0.0014	0.0127	CcSEcCtD
Nilutamide—Pneumonia—Sorafenib—liver cancer	0.00139	0.0125	CcSEcCtD
Nilutamide—Lung disorder—Epirubicin—liver cancer	0.00129	0.0116	CcSEcCtD
Nilutamide—Urinary tract disorder—Sorafenib—liver cancer	0.00123	0.0111	CcSEcCtD
Nilutamide—Urethral disorder—Sorafenib—liver cancer	0.00122	0.011	CcSEcCtD
Nilutamide—Lung disorder—Doxorubicin—liver cancer	0.00119	0.0108	CcSEcCtD
Nilutamide—Enzalutamide—ALB—liver cancer	0.00115	0.108	CrCbGaD
Nilutamide—Alopecia—Sorafenib—liver cancer	0.0011	0.00989	CcSEcCtD
Nilutamide—Anaemia—Sorafenib—liver cancer	0.000998	0.00901	CcSEcCtD
Nilutamide—Cough increased—Epirubicin—liver cancer	0.000997	0.009	CcSEcCtD
Nilutamide—Nocturia—Epirubicin—liver cancer	0.000984	0.00888	CcSEcCtD
Nilutamide—Syncope—Sorafenib—liver cancer	0.000969	0.00874	CcSEcCtD
Nilutamide—Leukopenia—Sorafenib—liver cancer	0.000967	0.00872	CcSEcCtD
Nilutamide—Creatinine increased—Epirubicin—liver cancer	0.000959	0.00865	CcSEcCtD
Nilutamide—Bone pain—Epirubicin—liver cancer	0.000953	0.0086	CcSEcCtD
Nilutamide—Loss of consciousness—Sorafenib—liver cancer	0.000949	0.00856	CcSEcCtD
Nilutamide—Cough—Sorafenib—liver cancer	0.000943	0.0085	CcSEcCtD
Nilutamide—Hypertension—Sorafenib—liver cancer	0.000933	0.00841	CcSEcCtD
Nilutamide—Cough increased—Doxorubicin—liver cancer	0.000923	0.00833	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Epirubicin—liver cancer	0.000913	0.00824	CcSEcCtD
Nilutamide—Nocturia—Doxorubicin—liver cancer	0.000911	0.00822	CcSEcCtD
Nilutamide—Dry mouth—Sorafenib—liver cancer	0.000899	0.00811	CcSEcCtD
Nilutamide—Melaena—Epirubicin—liver cancer	0.000892	0.00805	CcSEcCtD
Nilutamide—Creatinine increased—Doxorubicin—liver cancer	0.000888	0.00801	CcSEcCtD
Nilutamide—Bone pain—Doxorubicin—liver cancer	0.000882	0.00796	CcSEcCtD
Nilutamide—Shock—Sorafenib—liver cancer	0.000867	0.00782	CcSEcCtD
Nilutamide—Blood urea increased—Epirubicin—liver cancer	0.000862	0.00778	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.000845	0.00762	CcSEcCtD
Nilutamide—Anorexia—Sorafenib—liver cancer	0.00084	0.00758	CcSEcCtD
Nilutamide—Melaena—Doxorubicin—liver cancer	0.000825	0.00745	CcSEcCtD
Nilutamide—Blood urea increased—Doxorubicin—liver cancer	0.000798	0.0072	CcSEcCtD
Nilutamide—Abnormal vision—Epirubicin—liver cancer	0.000796	0.00718	CcSEcCtD
Nilutamide—Dyspnoea—Sorafenib—liver cancer	0.000786	0.00709	CcSEcCtD
Nilutamide—Dyspepsia—Sorafenib—liver cancer	0.000776	0.007	CcSEcCtD
Nilutamide—Decreased appetite—Sorafenib—liver cancer	0.000766	0.00691	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.000762	0.00688	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Sorafenib—liver cancer	0.000761	0.00687	CcSEcCtD
Nilutamide—Pain—Sorafenib—liver cancer	0.000754	0.0068	CcSEcCtD
Nilutamide—Constipation—Sorafenib—liver cancer	0.000754	0.0068	CcSEcCtD
Nilutamide—Abnormal vision—Doxorubicin—liver cancer	0.000737	0.00665	CcSEcCtD
Nilutamide—Gastrointestinal pain—Sorafenib—liver cancer	0.000721	0.0065	CcSEcCtD
Nilutamide—Hot flush—Epirubicin—liver cancer	0.000709	0.00639	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.000705	0.00636	CcSEcCtD
Nilutamide—Menopausal symptoms—Epirubicin—liver cancer	0.000702	0.00634	CcSEcCtD
Nilutamide—Abdominal pain—Sorafenib—liver cancer	0.000697	0.00629	CcSEcCtD
Nilutamide—Body temperature increased—Sorafenib—liver cancer	0.000697	0.00629	CcSEcCtD
Nilutamide—Cardiac failure—Epirubicin—liver cancer	0.000679	0.00613	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000663	0.00598	CcSEcCtD
Nilutamide—Hot flush—Doxorubicin—liver cancer	0.000656	0.00591	CcSEcCtD
Nilutamide—Menopausal symptoms—Doxorubicin—liver cancer	0.00065	0.00586	CcSEcCtD
Nilutamide—Asthenia—Sorafenib—liver cancer	0.000632	0.00571	CcSEcCtD
Nilutamide—Cardiac failure—Doxorubicin—liver cancer	0.000628	0.00567	CcSEcCtD
Nilutamide—Pruritus—Sorafenib—liver cancer	0.000624	0.00563	CcSEcCtD
Nilutamide—Blood creatinine increased—Epirubicin—liver cancer	0.000621	0.0056	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.000613	0.00553	CcSEcCtD
Nilutamide—Dry skin—Epirubicin—liver cancer	0.000608	0.00548	CcSEcCtD
Nilutamide—Diarrhoea—Sorafenib—liver cancer	0.000603	0.00544	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000597	0.00538	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000585	0.00527	CcSEcCtD
Nilutamide—Dizziness—Sorafenib—liver cancer	0.000583	0.00526	CcSEcCtD
Nilutamide—Blood creatinine increased—Doxorubicin—liver cancer	0.000575	0.00518	CcSEcCtD
Nilutamide—Influenza—Epirubicin—liver cancer	0.000573	0.00517	CcSEcCtD
Nilutamide—Dry skin—Doxorubicin—liver cancer	0.000562	0.00507	CcSEcCtD
Nilutamide—Vomiting—Sorafenib—liver cancer	0.00056	0.00506	CcSEcCtD
Nilutamide—Angina pectoris—Epirubicin—liver cancer	0.000558	0.00503	CcSEcCtD
Nilutamide—Rash—Sorafenib—liver cancer	0.000556	0.00501	CcSEcCtD
Nilutamide—Dermatitis—Sorafenib—liver cancer	0.000555	0.00501	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000552	0.00498	CcSEcCtD
Nilutamide—Headache—Sorafenib—liver cancer	0.000552	0.00498	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000541	0.00488	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Epirubicin—liver cancer	0.000532	0.0048	CcSEcCtD
Nilutamide—Influenza—Doxorubicin—liver cancer	0.00053	0.00478	CcSEcCtD
Nilutamide—Nausea—Sorafenib—liver cancer	0.000524	0.00472	CcSEcCtD
Nilutamide—Weight decreased—Epirubicin—liver cancer	0.000518	0.00468	CcSEcCtD
Nilutamide—Hyperglycaemia—Epirubicin—liver cancer	0.000517	0.00466	CcSEcCtD
Nilutamide—Angina pectoris—Doxorubicin—liver cancer	0.000516	0.00466	CcSEcCtD
Nilutamide—Pneumonia—Epirubicin—liver cancer	0.000514	0.00464	CcSEcCtD
Nilutamide—Urinary tract infection—Epirubicin—liver cancer	0.000497	0.00448	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000493	0.00444	CcSEcCtD
Nilutamide—Sweating—Epirubicin—liver cancer	0.00049	0.00442	CcSEcCtD
Nilutamide—Haematuria—Epirubicin—liver cancer	0.000487	0.00439	CcSEcCtD
Nilutamide—Weight decreased—Doxorubicin—liver cancer	0.00048	0.00433	CcSEcCtD
Nilutamide—Hyperglycaemia—Doxorubicin—liver cancer	0.000478	0.00431	CcSEcCtD
Nilutamide—Pneumonia—Doxorubicin—liver cancer	0.000475	0.00429	CcSEcCtD
Nilutamide—Rhinitis—Epirubicin—liver cancer	0.00046	0.00415	CcSEcCtD
Nilutamide—Urinary tract infection—Doxorubicin—liver cancer	0.000459	0.00414	CcSEcCtD
Nilutamide—Hypoaesthesia—Epirubicin—liver cancer	0.000456	0.00412	CcSEcCtD
Nilutamide—Sweating—Doxorubicin—liver cancer	0.000453	0.00409	CcSEcCtD
Nilutamide—Urinary tract disorder—Epirubicin—liver cancer	0.000453	0.00409	CcSEcCtD
Nilutamide—Oedema peripheral—Epirubicin—liver cancer	0.000452	0.00408	CcSEcCtD
Nilutamide—Haematuria—Doxorubicin—liver cancer	0.000451	0.00407	CcSEcCtD
Nilutamide—Urethral disorder—Epirubicin—liver cancer	0.00045	0.00406	CcSEcCtD
Nilutamide—Visual impairment—Epirubicin—liver cancer	0.000442	0.00399	CcSEcCtD
Nilutamide—Rhinitis—Doxorubicin—liver cancer	0.000425	0.00384	CcSEcCtD
Nilutamide—Hypoaesthesia—Doxorubicin—liver cancer	0.000422	0.00381	CcSEcCtD
Nilutamide—Urinary tract disorder—Doxorubicin—liver cancer	0.000419	0.00378	CcSEcCtD
Nilutamide—Oedema peripheral—Doxorubicin—liver cancer	0.000418	0.00377	CcSEcCtD
Nilutamide—Urethral disorder—Doxorubicin—liver cancer	0.000416	0.00375	CcSEcCtD
Nilutamide—Visual impairment—Doxorubicin—liver cancer	0.000409	0.00369	CcSEcCtD
Nilutamide—Alopecia—Epirubicin—liver cancer	0.000405	0.00366	CcSEcCtD
Nilutamide—Tension—Epirubicin—liver cancer	0.000392	0.00353	CcSEcCtD
Nilutamide—Nervousness—Epirubicin—liver cancer	0.000388	0.0035	CcSEcCtD
Nilutamide—Back pain—Epirubicin—liver cancer	0.000386	0.00348	CcSEcCtD
Nilutamide—Alopecia—Doxorubicin—liver cancer	0.000375	0.00338	CcSEcCtD
Nilutamide—Ill-defined disorder—Epirubicin—liver cancer	0.00037	0.00334	CcSEcCtD
Nilutamide—Anaemia—Epirubicin—liver cancer	0.000369	0.00333	CcSEcCtD
Nilutamide—Tension—Doxorubicin—liver cancer	0.000362	0.00327	CcSEcCtD
Nilutamide—Malaise—Epirubicin—liver cancer	0.00036	0.00325	CcSEcCtD
Nilutamide—Nervousness—Doxorubicin—liver cancer	0.000359	0.00324	CcSEcCtD
Nilutamide—Syncope—Epirubicin—liver cancer	0.000358	0.00323	CcSEcCtD
Nilutamide—Leukopenia—Epirubicin—liver cancer	0.000357	0.00322	CcSEcCtD
Nilutamide—Back pain—Doxorubicin—liver cancer	0.000357	0.00322	CcSEcCtD
Nilutamide—Loss of consciousness—Epirubicin—liver cancer	0.000351	0.00317	CcSEcCtD
Nilutamide—Cough—Epirubicin—liver cancer	0.000348	0.00314	CcSEcCtD
Nilutamide—Hypertension—Epirubicin—liver cancer	0.000345	0.00311	CcSEcCtD
Nilutamide—Ill-defined disorder—Doxorubicin—liver cancer	0.000343	0.00309	CcSEcCtD
Nilutamide—Anaemia—Doxorubicin—liver cancer	0.000341	0.00308	CcSEcCtD
Nilutamide—Chest pain—Epirubicin—liver cancer	0.00034	0.00307	CcSEcCtD
Nilutamide—Discomfort—Epirubicin—liver cancer	0.000336	0.00303	CcSEcCtD
Nilutamide—Malaise—Doxorubicin—liver cancer	0.000333	0.003	CcSEcCtD
Nilutamide—Dry mouth—Epirubicin—liver cancer	0.000332	0.003	CcSEcCtD
Nilutamide—Syncope—Doxorubicin—liver cancer	0.000331	0.00299	CcSEcCtD
Nilutamide—Leukopenia—Doxorubicin—liver cancer	0.000331	0.00298	CcSEcCtD
Nilutamide—Oedema—Epirubicin—liver cancer	0.000326	0.00294	CcSEcCtD
Nilutamide—Loss of consciousness—Doxorubicin—liver cancer	0.000325	0.00293	CcSEcCtD
Nilutamide—Cough—Doxorubicin—liver cancer	0.000322	0.00291	CcSEcCtD
Nilutamide—Shock—Epirubicin—liver cancer	0.000321	0.00289	CcSEcCtD
Nilutamide—Hypertension—Doxorubicin—liver cancer	0.000319	0.00288	CcSEcCtD
Nilutamide—Hyperhidrosis—Epirubicin—liver cancer	0.000315	0.00284	CcSEcCtD
Nilutamide—Chest pain—Doxorubicin—liver cancer	0.000314	0.00284	CcSEcCtD
Nilutamide—Discomfort—Doxorubicin—liver cancer	0.000311	0.0028	CcSEcCtD
Nilutamide—Anorexia—Epirubicin—liver cancer	0.000311	0.0028	CcSEcCtD
Nilutamide—Dry mouth—Doxorubicin—liver cancer	0.000308	0.00277	CcSEcCtD
Nilutamide—Oedema—Doxorubicin—liver cancer	0.000301	0.00272	CcSEcCtD
Nilutamide—Shock—Doxorubicin—liver cancer	0.000297	0.00268	CcSEcCtD
Nilutamide—Insomnia—Epirubicin—liver cancer	0.000295	0.00266	CcSEcCtD
Nilutamide—Paraesthesia—Epirubicin—liver cancer	0.000293	0.00264	CcSEcCtD
Nilutamide—Hyperhidrosis—Doxorubicin—liver cancer	0.000291	0.00263	CcSEcCtD
Nilutamide—Dyspnoea—Epirubicin—liver cancer	0.00029	0.00262	CcSEcCtD
Nilutamide—Anorexia—Doxorubicin—liver cancer	0.000287	0.00259	CcSEcCtD
Nilutamide—Dyspepsia—Epirubicin—liver cancer	0.000287	0.00259	CcSEcCtD
Nilutamide—Decreased appetite—Epirubicin—liver cancer	0.000283	0.00255	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Epirubicin—liver cancer	0.000281	0.00254	CcSEcCtD
Nilutamide—Pain—Epirubicin—liver cancer	0.000279	0.00251	CcSEcCtD
Nilutamide—Constipation—Epirubicin—liver cancer	0.000279	0.00251	CcSEcCtD
Nilutamide—Insomnia—Doxorubicin—liver cancer	0.000273	0.00246	CcSEcCtD
Nilutamide—Paraesthesia—Doxorubicin—liver cancer	0.000271	0.00244	CcSEcCtD
Nilutamide—Dyspnoea—Doxorubicin—liver cancer	0.000269	0.00242	CcSEcCtD
Nilutamide—Feeling abnormal—Epirubicin—liver cancer	0.000268	0.00242	CcSEcCtD
Nilutamide—Gastrointestinal pain—Epirubicin—liver cancer	0.000266	0.0024	CcSEcCtD
Nilutamide—Dyspepsia—Doxorubicin—liver cancer	0.000265	0.00239	CcSEcCtD
Nilutamide—Decreased appetite—Doxorubicin—liver cancer	0.000262	0.00236	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00026	0.00235	CcSEcCtD
Nilutamide—Pain—Doxorubicin—liver cancer	0.000258	0.00233	CcSEcCtD
Nilutamide—Constipation—Doxorubicin—liver cancer	0.000258	0.00233	CcSEcCtD
Nilutamide—Abdominal pain—Epirubicin—liver cancer	0.000258	0.00232	CcSEcCtD
Nilutamide—Body temperature increased—Epirubicin—liver cancer	0.000258	0.00232	CcSEcCtD
Nilutamide—Feeling abnormal—Doxorubicin—liver cancer	0.000248	0.00224	CcSEcCtD
Nilutamide—Gastrointestinal pain—Doxorubicin—liver cancer	0.000246	0.00222	CcSEcCtD
Nilutamide—Body temperature increased—Doxorubicin—liver cancer	0.000238	0.00215	CcSEcCtD
Nilutamide—Abdominal pain—Doxorubicin—liver cancer	0.000238	0.00215	CcSEcCtD
Nilutamide—Asthenia—Epirubicin—liver cancer	0.000234	0.00211	CcSEcCtD
Nilutamide—Pruritus—Epirubicin—liver cancer	0.00023	0.00208	CcSEcCtD
Nilutamide—Diarrhoea—Epirubicin—liver cancer	0.000223	0.00201	CcSEcCtD
Nilutamide—Asthenia—Doxorubicin—liver cancer	0.000216	0.00195	CcSEcCtD
Nilutamide—Dizziness—Epirubicin—liver cancer	0.000215	0.00194	CcSEcCtD
Nilutamide—Pruritus—Doxorubicin—liver cancer	0.000213	0.00192	CcSEcCtD
Nilutamide—Vomiting—Epirubicin—liver cancer	0.000207	0.00187	CcSEcCtD
Nilutamide—Diarrhoea—Doxorubicin—liver cancer	0.000206	0.00186	CcSEcCtD
Nilutamide—Rash—Epirubicin—liver cancer	0.000205	0.00185	CcSEcCtD
Nilutamide—Dermatitis—Epirubicin—liver cancer	0.000205	0.00185	CcSEcCtD
Nilutamide—Headache—Epirubicin—liver cancer	0.000204	0.00184	CcSEcCtD
Nilutamide—Dizziness—Doxorubicin—liver cancer	0.000199	0.0018	CcSEcCtD
Nilutamide—Nausea—Epirubicin—liver cancer	0.000194	0.00175	CcSEcCtD
Nilutamide—Vomiting—Doxorubicin—liver cancer	0.000192	0.00173	CcSEcCtD
Nilutamide—Rash—Doxorubicin—liver cancer	0.00019	0.00171	CcSEcCtD
Nilutamide—Dermatitis—Doxorubicin—liver cancer	0.00019	0.00171	CcSEcCtD
Nilutamide—Headache—Doxorubicin—liver cancer	0.000189	0.0017	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—NAT2—liver cancer	0.000184	0.00211	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.000183	0.0021	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000183	0.0021	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.000181	0.00207	CbGpPWpGaD
Nilutamide—Nausea—Doxorubicin—liver cancer	0.000179	0.00162	CcSEcCtD
Nilutamide—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.000178	0.00205	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GPX3—liver cancer	0.000175	0.00201	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.000172	0.00197	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—BRAF—liver cancer	0.000171	0.00196	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—NAT2—liver cancer	0.00017	0.00195	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.000168	0.00193	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDH1—liver cancer	0.000167	0.00192	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—HPGDS—liver cancer	0.000167	0.00192	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—HNF4A—liver cancer	0.000167	0.00191	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—liver cancer	0.000166	0.00191	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—liver cancer	0.000165	0.00189	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000165	0.00189	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—STAT3—liver cancer	0.000164	0.00189	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	0.000163	0.00187	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	0.00016	0.00183	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GPX3—liver cancer	0.000157	0.0018	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000155	0.00177	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—APC—liver cancer	0.000151	0.00173	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.00015	0.00172	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—HPGDS—liver cancer	0.000149	0.00171	CbGpPWpGaD
Nilutamide—AR—Gene Expression—EXOSC2—liver cancer	0.000148	0.0017	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—AKT1—liver cancer	0.000143	0.00164	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	0.000143	0.00164	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MTOR—liver cancer	0.000139	0.0016	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000138	0.00158	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP2E1—liver cancer	0.000136	0.00156	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—HPGDS—liver cancer	0.000136	0.00156	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP2E1—liver cancer	0.000134	0.00154	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CASP3—liver cancer	0.000128	0.00147	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000126	0.00144	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GGT1—liver cancer	0.000125	0.00144	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000125	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CCND1—liver cancer	0.000125	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—JUN—liver cancer	0.000125	0.00143	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—liver cancer	0.000124	0.00142	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP2E1—liver cancer	0.000122	0.0014	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—JUN—liver cancer	0.000121	0.00139	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.00012	0.00138	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP2E1—liver cancer	0.00012	0.00138	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	0.000118	0.00136	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NR1H4—liver cancer	0.000118	0.00135	CbGpPWpGaD
Nilutamide—AR—Gene Expression—NR1I3—liver cancer	0.000116	0.00133	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—liver cancer	0.000114	0.00131	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTP1—liver cancer	0.000112	0.00129	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GGT1—liver cancer	0.000112	0.00128	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP2E1—liver cancer	0.000111	0.00127	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTP1—liver cancer	0.000111	0.00127	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	0.000109	0.00125	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—liver cancer	0.000109	0.00125	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	0.000108	0.00124	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	0.000106	0.00122	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.000106	0.00122	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—AKT1—liver cancer	0.000106	0.00122	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	0.000103	0.00119	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—GSTM1—liver cancer	0.000103	0.00118	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	0.000103	0.00118	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	0.000102	0.00117	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GSTM1—liver cancer	0.000102	0.00117	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GGT1—liver cancer	0.000102	0.00117	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTP1—liver cancer	0.0001	0.00115	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—MYC—liver cancer	0.0001	0.00115	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	0.0001	0.00115	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	9.97e-05	0.00114	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTP1—liver cancer	9.9e-05	0.00114	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP1A1—liver cancer	9.79e-05	0.00112	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	9.77e-05	0.00112	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP1A1—liver cancer	9.66e-05	0.00111	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	9.61e-05	0.0011	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—liver cancer	9.25e-05	0.00106	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—GSTM1—liver cancer	9.22e-05	0.00106	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTP1—liver cancer	9.15e-05	0.00105	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GSTM1—liver cancer	9.1e-05	0.00104	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—TNF—liver cancer	9.09e-05	0.00104	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	9.02e-05	0.00103	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	9.02e-05	0.00103	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	8.9e-05	0.00102	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARA—liver cancer	8.75e-05	0.001	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP1A1—liver cancer	8.74e-05	0.001	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP1A1—liver cancer	8.62e-05	0.000989	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	8.58e-05	0.000984	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—GSTM1—liver cancer	8.41e-05	0.000964	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	8.3e-05	0.000952	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	8.29e-05	0.000951	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	8.28e-05	0.000949	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—liver cancer	8.22e-05	0.000943	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	8.11e-05	0.00093	CbGpPWpGaD
Nilutamide—AR—Gene Expression—HNF4A—liver cancer	8.02e-05	0.000919	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP1A1—liver cancer	7.97e-05	0.000914	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR1—liver cancer	7.92e-05	0.000909	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	7.86e-05	0.000902	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	7.82e-05	0.000897	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	7.73e-05	0.000886	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	7.67e-05	0.000879	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	7.35e-05	0.000843	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—IL6—liver cancer	7.33e-05	0.000841	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—UGDH—liver cancer	7.33e-05	0.00084	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PPARG—liver cancer	7.23e-05	0.000829	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	7.04e-05	0.000808	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSMA4—liver cancer	7.01e-05	0.000804	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PSMD10—liver cancer	7.01e-05	0.000804	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—AKT1—liver cancer	6.94e-05	0.000796	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—EPT1—liver cancer	6.89e-05	0.00079	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	6.81e-05	0.000782	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	6.56e-05	0.000752	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—UGDH—liver cancer	6.54e-05	0.00075	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—TAT—liver cancer	6.53e-05	0.000749	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—SERPINE1—liver cancer	6.51e-05	0.000747	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	6.42e-05	0.000736	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—EPT1—liver cancer	6.15e-05	0.000705	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	5.98e-05	0.000686	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—UGDH—liver cancer	5.96e-05	0.000684	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—TAT—liver cancer	5.83e-05	0.000668	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	5.75e-05	0.00066	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	5.73e-05	0.000657	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—EPT1—liver cancer	5.61e-05	0.000643	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—TAT—liver cancer	5.31e-05	0.000609	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	5.23e-05	0.000599	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.81e-05	0.000551	CbGpPWpGaD
Nilutamide—AR—Gene Expression—H2AFX—liver cancer	4.73e-05	0.000543	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GLUL—liver cancer	4.44e-05	0.000509	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CPT1B—liver cancer	4.44e-05	0.000509	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—liver cancer	4.29e-05	0.000492	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NR1H4—liver cancer	4.28e-05	0.000491	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARA—liver cancer	4.21e-05	0.000483	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTA3—liver cancer	4.21e-05	0.000483	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—MYC—liver cancer	4.12e-05	0.000473	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CPT1B—liver cancer	3.96e-05	0.000454	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GLUL—liver cancer	3.96e-05	0.000454	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	3.91e-05	0.000449	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MAPK14—liver cancer	3.89e-05	0.000446	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTA4—liver cancer	3.85e-05	0.000441	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NR1H4—liver cancer	3.82e-05	0.000438	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR1—liver cancer	3.82e-05	0.000438	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.76e-05	0.000431	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTA3—liver cancer	3.76e-05	0.000431	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTA2—liver cancer	3.75e-05	0.00043	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTA1—liver cancer	3.62e-05	0.000415	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CPT1B—liver cancer	3.61e-05	0.000414	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GLUL—liver cancer	3.61e-05	0.000414	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NAT2—liver cancer	3.58e-05	0.00041	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NR1H4—liver cancer	3.48e-05	0.000399	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PPARG—liver cancer	3.48e-05	0.000399	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.44e-05	0.000395	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTA4—liver cancer	3.43e-05	0.000394	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALDOB—liver cancer	3.43e-05	0.000393	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTA3—liver cancer	3.42e-05	0.000393	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.36e-05	0.000385	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTA2—liver cancer	3.35e-05	0.000384	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CRABP1—liver cancer	3.27e-05	0.000375	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTA1—liver cancer	3.23e-05	0.00037	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NAT2—liver cancer	3.19e-05	0.000366	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SERPINE1—liver cancer	3.14e-05	0.00036	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTA4—liver cancer	3.13e-05	0.000359	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.07e-05	0.000352	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALDOB—liver cancer	3.06e-05	0.000351	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.06e-05	0.000351	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTA2—liver cancer	3.05e-05	0.00035	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.95e-05	0.000338	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTA1—liver cancer	2.94e-05	0.000338	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CRABP1—liver cancer	2.92e-05	0.000335	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NAT2—liver cancer	2.91e-05	0.000334	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HPGDS—liver cancer	2.86e-05	0.000328	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.84e-05	0.000326	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.8e-05	0.000321	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALDOB—liver cancer	2.79e-05	0.00032	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CRABP1—liver cancer	2.66e-05	0.000305	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.63e-05	0.000302	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.59e-05	0.000297	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.56e-05	0.000293	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HPGDS—liver cancer	2.55e-05	0.000293	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSMD10—liver cancer	2.55e-05	0.000292	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PSMA4—liver cancer	2.55e-05	0.000292	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.54e-05	0.000291	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GOT2—liver cancer	2.48e-05	0.000284	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	2.4e-05	0.000275	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP2E1—liver cancer	2.33e-05	0.000267	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HPGDS—liver cancer	2.33e-05	0.000267	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	2.31e-05	0.000265	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.31e-05	0.000265	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.28e-05	0.000262	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSMA4—liver cancer	2.28e-05	0.000261	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PSMD10—liver cancer	2.28e-05	0.000261	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.26e-05	0.000259	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GOT2—liver cancer	2.21e-05	0.000254	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYCS—liver cancer	2.18e-05	0.00025	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GGT1—liver cancer	2.14e-05	0.000245	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GOT1—liver cancer	2.14e-05	0.000245	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.11e-05	0.000242	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP2E1—liver cancer	2.08e-05	0.000239	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.08e-05	0.000239	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSMA4—liver cancer	2.07e-05	0.000238	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PSMD10—liver cancer	2.07e-05	0.000238	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GOT2—liver cancer	2.02e-05	0.000231	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.01e-05	0.000231	CbGpPWpGaD
Nilutamide—AR—Gene Expression—MYC—liver cancer	1.98e-05	0.000228	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYCS—liver cancer	1.95e-05	0.000223	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTP1—liver cancer	1.92e-05	0.000221	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GOT1—liver cancer	1.91e-05	0.000219	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GGT1—liver cancer	1.91e-05	0.000219	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP2E1—liver cancer	1.9e-05	0.000218	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—HMOX1—liver cancer	1.9e-05	0.000217	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.84e-05	0.000211	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYCS—liver cancer	1.78e-05	0.000204	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—GSTM1—liver cancer	1.77e-05	0.000203	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GGT1—liver cancer	1.74e-05	0.0002	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GOT1—liver cancer	1.74e-05	0.0002	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTP1—liver cancer	1.72e-05	0.000197	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—HMOX1—liver cancer	1.69e-05	0.000194	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP1A1—liver cancer	1.67e-05	0.000192	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—GSTM1—liver cancer	1.58e-05	0.000181	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTP1—liver cancer	1.56e-05	0.000179	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MTHFR—liver cancer	1.56e-05	0.000179	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—HMOX1—liver cancer	1.54e-05	0.000177	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARA—liver cancer	1.53e-05	0.000176	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP1A1—liver cancer	1.5e-05	0.000171	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—GSTM1—liver cancer	1.44e-05	0.000165	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MTHFR—liver cancer	1.39e-05	0.00016	CbGpPWpGaD
Nilutamide—AR—Gene Expression—AKT1—liver cancer	1.38e-05	0.000158	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.38e-05	0.000158	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARA—liver cancer	1.37e-05	0.000157	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP1A1—liver cancer	1.36e-05	0.000156	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CG—liver cancer	1.31e-05	0.00015	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MTHFR—liver cancer	1.27e-05	0.000146	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PPARG—liver cancer	1.27e-05	0.000145	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARA—liver cancer	1.25e-05	0.000143	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.23e-05	0.000141	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CG—liver cancer	1.17e-05	0.000134	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CD—liver cancer	1.15e-05	0.000132	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—ALB—liver cancer	1.14e-05	0.000131	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PPARG—liver cancer	1.13e-05	0.00013	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.12e-05	0.000128	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CG—liver cancer	1.07e-05	0.000122	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PPARG—liver cancer	1.03e-05	0.000118	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CD—liver cancer	1.03e-05	0.000118	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—ALB—liver cancer	1.02e-05	0.000117	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CB—liver cancer	1.01e-05	0.000115	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CD—liver cancer	9.39e-06	0.000108	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—ALB—liver cancer	9.27e-06	0.000106	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CB—liver cancer	8.97e-06	0.000103	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CB—liver cancer	8.18e-06	9.38e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—liver cancer	6.13e-06	7.03e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—liver cancer	5.47e-06	6.27e-05	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKT1—liver cancer	5.01e-06	5.74e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—liver cancer	4.99e-06	5.72e-05	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKT1—liver cancer	4.47e-06	5.12e-05	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKT1—liver cancer	4.07e-06	4.67e-05	CbGpPWpGaD
